<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/43A66959-3A72-45B7-BE4A-FB71CAC822E6"><gtr:id>43A66959-3A72-45B7-BE4A-FB71CAC822E6</gtr:id><gtr:firstName>Shitij</gtr:firstName><gtr:surname>Kapur</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701748"><gtr:id>E2EE7886-78F7-4C68-9BB3-120839782ED6</gtr:id><gtr:title>Strategic Appointment of Dr Shitij Kapur</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701748</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2012-01-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1000000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>NEWMEDS Workpackage 3</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E104A854-6FB6-4C4E-81A6-36CCDC861FF6</gtr:id><gtr:impact>Mainly a talk targeted to drug developers who are a part of the NEWMEDS collaboration to help them with a better design of the clinical trial that is to be a part of the NEWMEDS collaboration.

The new clinical trial, with patients with Schizophrenia, is informed by the design and success of our MRC funded efforts.</gtr:impact><gtr:outcomeId>ZWhBDhkJrRw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>392739</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DC3EC94E-C9F2-42E6-8F55-355697A244A8</gtr:id><gtr:outcomeId>546494610caf08.21588026</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>819689</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>252A370E-90DC-4508-BE6B-A1869E1EDDEE</gtr:id><gtr:outcomeId>VCEDVF1YjLy0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU IMI-JU Project</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>21E3881F-30B0-4222-8054-C9C95F62F4C6</gtr:id><gtr:outcomeId>37B7663D5780</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1A003D63-E83D-4ED0-8162-F2D0674FCA72</gtr:id><gtr:title>Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.</gtr:title><gtr:parentPublicationTitle>Pharmacopsychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/518f3e6a18f6877a60c6cc9ca4a55d6c"><gtr:id>518f3e6a18f6877a60c6cc9ca4a55d6c</gtr:id><gtr:otherNames>Naber D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0176-3679</gtr:issn><gtr:outcomeId>569d0555aefc71.09833799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CC3A8C5-FEA8-46BA-80A1-F876640287D6</gtr:id><gtr:title>Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/281992eb4b1dc6a1a431ed9ef2359b93"><gtr:id>281992eb4b1dc6a1a431ed9ef2359b93</gtr:id><gtr:otherNames>Vernon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>VhDBfFoQSRv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>875FAA97-D4CC-4634-8928-44EDF007899D</gtr:id><gtr:title>Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94826691463807f1ed1d1842fd16e639"><gtr:id>94826691463807f1ed1d1842fd16e639</gtr:id><gtr:otherNames>Marder SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>569d0553c23af9.72025176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCD4DFF4-7422-4F6E-A228-35D712CC928C</gtr:id><gtr:title>Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17d44ba270474f119b4f3461a9697553"><gtr:id>17d44ba270474f119b4f3461a9697553</gtr:id><gtr:otherNames>Rabinowitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d0552c6f074.52366546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87B2A506-AA48-4715-AF0F-6617266AC0B9</gtr:id><gtr:title>A comparison of two delivery modalities of a mobile phone-based assessment for serious mental illness: native smartphone application vs text-messaging only implementations.</gtr:title><gtr:parentPublicationTitle>Journal of medical Internet research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01324b0f75bfb2ffd6683510790c39dd"><gtr:id>01324b0f75bfb2ffd6683510790c39dd</gtr:id><gtr:otherNames>Ainsworth J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1438-8871</gtr:issn><gtr:outcomeId>569d05554a07c6.73096552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9B0FA65-15A8-4019-8577-754A41433887</gtr:id><gtr:title>Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/281992eb4b1dc6a1a431ed9ef2359b93"><gtr:id>281992eb4b1dc6a1a431ed9ef2359b93</gtr:id><gtr:otherNames>Vernon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_16114_24_24143881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7D1BE30-A74C-442E-9433-C3D155DB1CC8</gtr:id><gtr:title>Changes in delusions in the early phase of antipsychotic treatment - an experience sampling study.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95fd0449b0ada08db7d21fdf46b29b32"><gtr:id>95fd0449b0ada08db7d21fdf46b29b32</gtr:id><gtr:otherNames>So SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>569d05529c3ee6.85715087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9839918-683E-466A-8F33-F631780FE1CC</gtr:id><gtr:title>The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>569d0551a68d69.96010047</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EFAE531-EDE6-46C4-B9CE-1DFEC2FCF649</gtr:id><gtr:title>Jumping to conclusions, a lack of belief flexibility and delusional conviction in psychosis: a longitudinal investigation of the structure, frequency, and relatedness of reasoning biases.</gtr:title><gtr:parentPublicationTitle>Journal of abnormal psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95fd0449b0ada08db7d21fdf46b29b32"><gtr:id>95fd0449b0ada08db7d21fdf46b29b32</gtr:id><gtr:otherNames>So SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-843X</gtr:issn><gtr:outcomeId>pm_16114_24_21910515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41A9B3E1-D1A1-485A-9396-72170C050A6A</gtr:id><gtr:title>Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17d44ba270474f119b4f3461a9697553"><gtr:id>17d44ba270474f119b4f3461a9697553</gtr:id><gtr:otherNames>Rabinowitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0160-6689</gtr:issn><gtr:outcomeId>569d05517f9244.64754259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69075A56-3C9A-4C64-8994-AABED534028F</gtr:id><gtr:title>Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [&amp;sup1;&amp;sup1;C]MP-10 PET rodent imaging study with ex vivo confirmation.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d801f6fdc39566df69eaf9846ac057bd"><gtr:id>d801f6fdc39566df69eaf9846ac057bd</gtr:id><gtr:otherNames>Natesan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>569d0552001152.72391905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67EB0E82-8A3F-4AD0-9006-DD9190CAFAE8</gtr:id><gtr:title>Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84eb9fe0d983c60009837884ae092df8"><gtr:id>84eb9fe0d983c60009837884ae092df8</gtr:id><gtr:otherNames>Bugarski-Kirola D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>58b9a516ea94d8.96988591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>917260DB-CFA9-47E4-BD70-849656425228</gtr:id><gtr:title>The effects of a single dose of oxytocin on working memory in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1a177c3776894bed85188307ec59ba8"><gtr:id>f1a177c3776894bed85188307ec59ba8</gtr:id><gtr:otherNames>Michalopoulou PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>569d0550208e62.07828459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73FEB49B-5425-496F-8A41-7E7123D957F6</gtr:id><gtr:title>Molecular imaging as a guide for the treatment of central nervous system disorders.</gtr:title><gtr:parentPublicationTitle>Dialogues in clinical neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1294-8322</gtr:issn><gtr:outcomeId>569d05537619f6.42381002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62C4D832-3FBF-471B-9206-1AEB66FEEDBB</gtr:id><gtr:title>Impaired subjective well-being in schizophrenia is associated with reduced anterior cingulate activity during reward processing.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8d804082c34afb1e62e2193a864b2a8"><gtr:id>d8d804082c34afb1e62e2193a864b2a8</gtr:id><gtr:otherNames>Gilleen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>569d0550696d29.79374360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49BED9D-2E85-4F11-B044-5512FF83772A</gtr:id><gtr:title>Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>569d05549dbdd5.54885415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7AC64C3-94CD-4E6F-AE1C-A9FB53556F06</gtr:id><gtr:title>Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1a177c3776894bed85188307ec59ba8"><gtr:id>f1a177c3776894bed85188307ec59ba8</gtr:id><gtr:otherNames>Michalopoulou PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d054ea3e0c9.70484658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45361056-B380-4EB8-A8F4-1A43923961E3</gtr:id><gtr:title>The promise of biological markers for treatment response in first-episode psychosis: a systematic review.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e36d1f10469ff9a8db946ab0d17e01a"><gtr:id>9e36d1f10469ff9a8db946ab0d17e01a</gtr:id><gtr:otherNames>Fond G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>569d054febc1e1.89642497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0B61790-778B-4E94-8CA6-B7B14D694139</gtr:id><gtr:title>Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e32dbac114694e2bb6186e6f5488ea5"><gtr:id>9e32dbac114694e2bb6186e6f5488ea5</gtr:id><gtr:otherNames>Kinon BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>70AC4B830FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF882180-ADA7-4130-A9F1-379F6322B8E7</gtr:id><gtr:title>Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9c8402918ea8e3bd47a06f8f7680221"><gtr:id>e9c8402918ea8e3bd47a06f8f7680221</gtr:id><gtr:otherNames>Wilson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>58b9a517deba21.34582761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>566C2D26-6963-4FC5-BDCA-098828C7F4F8</gtr:id><gtr:title>Detecting improvements in acute psychotic symptoms using experience sampling methodology.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95fd0449b0ada08db7d21fdf46b29b32"><gtr:id>95fd0449b0ada08db7d21fdf46b29b32</gtr:id><gtr:otherNames>So SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>569d0554798ed1.39024356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC449A6A-18D3-41D7-BCF2-7FCF59D2DA6E</gtr:id><gtr:title>Schizophrenia.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af09b1af6bba454035877ef677af72c3"><gtr:id>af09b1af6bba454035877ef677af72c3</gtr:id><gtr:otherNames>van Os J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>BA8149B445F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>318A4B7D-CC1C-4B69-91D3-65E8AB81F2BA</gtr:id><gtr:title>Phosphodiesterase 10A PET radioligand development program: from pig to human.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c5f70f3e3a3baa48707f9cb621a7b23"><gtr:id>1c5f70f3e3a3baa48707f9cb621a7b23</gtr:id><gtr:otherNames>Plisson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>569d055228cc01.08497685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2702F414-D676-4F4F-8941-5F816E26ADB7</gtr:id><gtr:title>Negative symptoms in schizophrenia--the remarkable impact of inclusion definitions in clinical trials and their consequences.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17d44ba270474f119b4f3461a9697553"><gtr:id>17d44ba270474f119b4f3461a9697553</gtr:id><gtr:otherNames>Rabinowitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>569d0554c37a24.18823357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DF9264E-D672-4C4B-883B-B94CD00FF2B3</gtr:id><gtr:title>Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60d0ca1e50fddc2c7c76dbba217a19c0"><gtr:id>60d0ca1e50fddc2c7c76dbba217a19c0</gtr:id><gtr:otherNames>Cotel MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d054d4bbe61.19241994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1953876A-80C6-4EFF-9409-F5E63D675699</gtr:id><gtr:title>Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b552ca47113d2a2151ef284e00dc4bcd"><gtr:id>b552ca47113d2a2151ef284e00dc4bcd</gtr:id><gtr:otherNames>Sim F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>569d05508ff064.39355667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A89B071-1A33-4E3B-AF46-1417D194BDA8</gtr:id><gtr:title>Sensorimotor gating, cannabis use and the risk of psychosis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f6cef822f5d20e0ff787c52c312664d"><gtr:id>7f6cef822f5d20e0ff787c52c312664d</gtr:id><gtr:otherNames>Winton-Brown T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>569d054f58eda3.29718700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC57B2D5-A9D8-4E35-9C9D-8E6A82348E4B</gtr:id><gtr:title>Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11508573495ec68045c64e215be2f37e"><gtr:id>11508573495ec68045c64e215be2f37e</gtr:id><gtr:otherNames>Mourao-Miranda J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_16114_24_22059690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71231DCB-6AA5-4D06-81A3-757F9E69180E</gtr:id><gtr:title>CNVs conferring risk of autism or schizophrenia affect cognition in controls.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/610f621d35dbf22d875515e6c6d91820"><gtr:id>610f621d35dbf22d875515e6c6d91820</gtr:id><gtr:otherNames>Stefansson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>569d0552eb1075.55832824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1974750D-3FFA-4CCE-9FDF-E2622A5A1E67</gtr:id><gtr:title>White matter integrity as a predictor of response to treatment in first episode psychosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/284b6865f1c729f54a5a38c398131efe"><gtr:id>284b6865f1c729f54a5a38c398131efe</gtr:id><gtr:otherNames>Reis Marques T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>569d05531dc989.96938482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84B62790-75C4-497D-82D9-4F94494F13CF</gtr:id><gtr:title>Do antipsychotics improve reasoning biases? A review.</gtr:title><gtr:parentPublicationTitle>Psychosomatic medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95fd0449b0ada08db7d21fdf46b29b32"><gtr:id>95fd0449b0ada08db7d21fdf46b29b32</gtr:id><gtr:otherNames>So SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-3174</gtr:issn><gtr:outcomeId>ewXgsdGcyZt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AB3DE4C-AC7E-40D0-B068-B924FFA45E3B</gtr:id><gtr:title>Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f97baa8e5ebb1e342f4eaf589b393a"><gtr:id>b1f97baa8e5ebb1e342f4eaf589b393a</gtr:id><gtr:otherNames>Marques TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>585d7345218359.61446048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDCFF9E0-DFC7-4131-967F-F6818D0CBACC</gtr:id><gtr:title>The neurobiology of schizophrenia: new leads and avenues for treatment.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/135e9ad2f70b3d6a351d48ef72de104c"><gtr:id>135e9ad2f70b3d6a351d48ef72de104c</gtr:id><gtr:otherNames>Bray NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-4388</gtr:issn><gtr:outcomeId>oPX5RcHg3As</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>431688FD-442F-4460-8EFC-8D2B75984713</gtr:id><gtr:title>Calibration and cross-validation of MCCB and CogState in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6099180ea70dfdee1490fe39395dca9"><gtr:id>f6099180ea70dfdee1490fe39395dca9</gtr:id><gtr:otherNames>Lees J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>569d054e7cc0f5.57957371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FDB529C-BC9E-4BB5-A8FF-5A50FBFA6FE2</gtr:id><gtr:title>Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_16114_24_22186667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FA13310-25AC-4566-939B-901488B8892D</gtr:id><gtr:title>Changes in delusional dimensions and emotions over eight weeks of antipsychotic treatment in acute patients.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95fd0449b0ada08db7d21fdf46b29b32"><gtr:id>95fd0449b0ada08db7d21fdf46b29b32</gtr:id><gtr:otherNames>So SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>569d054e0f88a5.48199332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8402DC21-993A-4D3E-BC03-DA10DD055289</gtr:id><gtr:title>Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17d44ba270474f119b4f3461a9697553"><gtr:id>17d44ba270474f119b4f3461a9697553</gtr:id><gtr:otherNames>Rabinowitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>58b9a51734cb23.46194843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C44D55F3-7E3F-4A41-914F-08F40F9283D7</gtr:id><gtr:title>Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dbe7183e011b5774210914fa10e902b"><gtr:id>1dbe7183e011b5774210914fa10e902b</gtr:id><gtr:otherNames>Sparshatt A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0160-6689</gtr:issn><gtr:outcomeId>e59yAP2Mm6R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>340D4AF4-0471-4819-AE68-F4AF6790F1ED</gtr:id><gtr:title>Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ee9b25236b393d75d000608a6adf1f2"><gtr:id>5ee9b25236b393d75d000608a6adf1f2</gtr:id><gtr:otherNames>Dunn JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>569d055520d074.50182463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62DE82A2-5F30-47D7-BF87-864BDCC5442D</gtr:id><gtr:title>Connectomic correlates of response to treatment in first-episode psychosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec44ca54f345ce2e2233cb84e90a372b"><gtr:id>ec44ca54f345ce2e2233cb84e90a372b</gtr:id><gtr:otherNames>Crossley NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58b9a516c44a63.84243394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93A54E19-1BA4-450E-98D3-1055B0172213</gtr:id><gtr:title>Microvascular abnormality in schizophrenia as shown by retinal imaging.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e58db17a6bc2b57b29aec1b2c18e55f9"><gtr:id>e58db17a6bc2b57b29aec1b2c18e55f9</gtr:id><gtr:otherNames>Meier MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>569d0553a093c6.80143572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A63E77AE-42D9-4824-970F-E24425B1996D</gtr:id><gtr:title>Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62d8d5dd3724d264b7dc87b51e6f11a0"><gtr:id>62d8d5dd3724d264b7dc87b51e6f11a0</gtr:id><gtr:otherNames>Crum WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5a35da62c008a2.37415518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>048313FE-10EA-4A6A-8CB0-314F967871A5</gtr:id><gtr:title>Clinically meaningful biomarkers for psychosis: a systematic and quantitative review.</gtr:title><gtr:parentPublicationTitle>Neuroscience and biobehavioral reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db98fb67f0c9025c7bc35a474cb38d44"><gtr:id>db98fb67f0c9025c7bc35a474cb38d44</gtr:id><gtr:otherNames>Prata D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-7634</gtr:issn><gtr:outcomeId>569d05512db313.42082780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3E6F4F0-591B-4AEC-82BB-2E666682EA2E</gtr:id><gtr:title>How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f97baa8e5ebb1e342f4eaf589b393a"><gtr:id>b1f97baa8e5ebb1e342f4eaf589b393a</gtr:id><gtr:otherNames>Marques TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d0551574537.28790880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F468CE66-2CA7-4D25-BC21-012A48122B5F</gtr:id><gtr:title>Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b48799262f9cd281765d37763d4693d"><gtr:id>2b48799262f9cd281765d37763d4693d</gtr:id><gtr:otherNames>Levine SZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d054e57f6d7.34033172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5345993A-0FF0-41CF-9D2D-97CC94987B1E</gtr:id><gtr:title>A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>569d0551011940.96403044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E8781B6-2D4E-49D7-9506-714B37037A6B</gtr:id><gtr:title>Translating genome-wide association findings into new therapeutics for psychiatry.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b860966e744e7b358bf4b24c1965670d"><gtr:id>b860966e744e7b358bf4b24c1965670d</gtr:id><gtr:otherNames>Breen G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>58b9a517b79e95.81044758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FB83DEB-9E55-445F-B429-8B4A8E0BCF42</gtr:id><gtr:title>Pharmacogenetics in psychiatry: are we ready for widespread clinical use?</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/573ef969079a724c3f481a0da796caf1"><gtr:id>573ef969079a724c3f481a0da796caf1</gtr:id><gtr:otherNames>Arranz MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>BE29EBDEFB1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B63B46FE-9457-40C6-8B90-D2FCD214AEAA</gtr:id><gtr:title>Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration.</gtr:title><gtr:parentPublicationTitle>Behavioural brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03619b763704fd6cda232055c285197d"><gtr:id>03619b763704fd6cda232055c285197d</gtr:id><gtr:otherNames>Amato D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0166-4328</gtr:issn><gtr:outcomeId>bVvMWuJgZ1E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4E3DBC7-56E4-46F0-BE81-342336A4077A</gtr:id><gtr:title>Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.</gtr:title><gtr:parentPublicationTitle>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0ab66c8ac12e80e573f36c35ef49d92"><gtr:id>a0ab66c8ac12e80e573f36c35ef49d92</gtr:id><gtr:otherNames>Uchida H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-7481</gtr:issn><gtr:outcomeId>E1A4E4E86E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50ED5E52-5E13-469F-9A2F-B0A5F16EC216</gtr:id><gtr:title>Modafinil combined with cognitive training is associated with improved learning in healthy volunteers--a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8d804082c34afb1e62e2193a864b2a8"><gtr:id>d8d804082c34afb1e62e2193a864b2a8</gtr:id><gtr:otherNames>Gilleen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d0552505514.00696474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35E04A3A-0D1C-4AAA-BC5E-8E3CB98F2B2D</gtr:id><gtr:title>The different trajectories of antipsychotic response: antipsychotics versus placebo.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1f97baa8e5ebb1e342f4eaf589b393a"><gtr:id>b1f97baa8e5ebb1e342f4eaf589b393a</gtr:id><gtr:otherNames>Marques TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>QPPY61NiEYb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1072EDDD-226F-43E4-B204-ED25337C01EB</gtr:id><gtr:title>Copy number variants and therapeutic response to antidepressant medication in major depressive disorder.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ada3ea3786a6a31983bfd2ca653851"><gtr:id>56ada3ea3786a6a31983bfd2ca653851</gtr:id><gtr:otherNames>Tansey KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>569d05527933f0.17003688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F247B0AC-4D2D-4441-9249-AB81A86B901A</gtr:id><gtr:title>The dopamine hypothesis of schizophrenia: version III--the final common pathway.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>CA579499169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66DA2D22-9F99-4611-A318-27C2F190F821</gtr:id><gtr:title>Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8baee9767245f3e6d3dfcffe627a7590"><gtr:id>8baee9767245f3e6d3dfcffe627a7590</gtr:id><gtr:otherNames>Kapur S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>569d054c8ca551.86703800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A128B270-D62D-469A-B147-89806D5673FC</gtr:id><gtr:title>The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30b0216384060a4ecdaf9e25a17b961c"><gtr:id>30b0216384060a4ecdaf9e25a17b961c</gtr:id><gtr:otherNames>Kim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>569d0555e54249.15427807</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09862D74-7035-41D4-A837-3D12F7A6C1E6</gtr:id><gtr:title>Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d801f6fdc39566df69eaf9846ac057bd"><gtr:id>d801f6fdc39566df69eaf9846ac057bd</gtr:id><gtr:otherNames>Natesan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>goDP2VRfxer</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9332D957-3D08-4A2E-BED1-DBCC821005E4</gtr:id><gtr:title>Effects of haloperidol and aripiprazole on the human mesolimbic motivational system: A pharmacological fMRI study.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be38b43c8c8549ce7145b8bb94b8e444"><gtr:id>be38b43c8c8549ce7145b8bb94b8e444</gtr:id><gtr:otherNames>Bolstad I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d054cb8c394.41236011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B7FE89C-A17C-4644-AB6D-71535E05B1C7</gtr:id><gtr:title>NEWMEDS special issue commentary.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5b7d49989d37d8f2495111ec915f287"><gtr:id>f5b7d49989d37d8f2495111ec915f287</gtr:id><gtr:otherNames>Stensb?l TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>569d054d247fa9.69933153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08E652C5-C88A-4AC7-9CE2-56B40E2F0168</gtr:id><gtr:title>Predicting clinical response in people at ultra-high risk of psychosis: a systematic and quantitative review.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7e80c50cd776b047fcf989b44a0ba38"><gtr:id>d7e80c50cd776b047fcf989b44a0ba38</gtr:id><gtr:otherNames>Mechelli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>569d054f9ba955.05890703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BF10846-655F-4F34-AAE4-C85C132A4214</gtr:id><gtr:title>Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.</gtr:title><gtr:parentPublicationTitle>Human brain mapping</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5856049172aa2e92ea9cfe994242efe5"><gtr:id>5856049172aa2e92ea9cfe994242efe5</gtr:id><gtr:otherNames>Handley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1065-9471</gtr:issn><gtr:outcomeId>pm_16114_24_22451196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15AEA9FC-7C4D-4688-8749-1CEAB281797D</gtr:id><gtr:title>Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3ce08ceec98a04db08d08c4ff7cfc14"><gtr:id>c3ce08ceec98a04db08d08c4ff7cfc14</gtr:id><gtr:otherNames>Sakurai H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0160-6689</gtr:issn><gtr:outcomeId>58b9a51760a4b5.88645892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F54BD7BD-48CB-4845-BCCA-D821E48CF4EE</gtr:id><gtr:title>Alterations of the brain reward system in antipsychotic na&amp;iuml;ve schizophrenia patients.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c736712989781ca45cf3230012f3bf5"><gtr:id>4c736712989781ca45cf3230012f3bf5</gtr:id><gtr:otherNames>Nielsen M?</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_16114_24_22418013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C70C1806-BE15-4E9B-A595-6D0B63FC7BE5</gtr:id><gtr:title>Polypharmacy: the good, the bad and the ugly.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04dea61d60238102bf80e161b6ef9dbd"><gtr:id>04dea61d60238102bf80e161b6ef9dbd</gtr:id><gtr:otherNames>Fleischhacker WW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>569d0553e53146.64665318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A6AD088-344B-438F-AD2F-07C42C188B5D</gtr:id><gtr:title>Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9eafe896fda435f3a07d920b34b4cc32"><gtr:id>9eafe896fda435f3a07d920b34b4cc32</gtr:id><gtr:otherNames>Remington G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-0749</gtr:issn><gtr:outcomeId>pm_16114_24_22198452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E391000-004C-494F-A103-128228A1D235</gtr:id><gtr:title>Securing the future of drug discovery for central nervous system disorders.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78434a04a419ae0cdae52efdc03d616a"><gtr:id>78434a04a419ae0cdae52efdc03d616a</gtr:id><gtr:otherNames>Andersen PH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>569d055046d993.75374319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3997C9D-9F3C-42CC-983E-547ACDD8724C</gtr:id><gtr:title>Pharmacogenetics of antidepressant response: A polygenic approach.</gtr:title><gtr:parentPublicationTitle>Progress in neuro-psychopharmacology &amp; biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0a508ff3aae20e3481498a8129901ba"><gtr:id>f0a508ff3aae20e3481498a8129901ba</gtr:id><gtr:otherNames>Garc?a-Gonz?lez J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0278-5846</gtr:issn><gtr:outcomeId>58b9a517904215.88050495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>883ED261-5766-4CE1-8E78-BEF713534D94</gtr:id><gtr:title>Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: A longitudinal in vivo MRI study.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62d8d5dd3724d264b7dc87b51e6f11a0"><gtr:id>62d8d5dd3724d264b7dc87b51e6f11a0</gtr:id><gtr:otherNames>Crum WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>5a3514ba6e2eb0.80586349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D3F59CE-D48F-4B1F-A624-7C1AE33E7CD7</gtr:id><gtr:title>Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d27a275f92af81823493d6f34af1f3"><gtr:id>40d27a275f92af81823493d6f34af1f3</gtr:id><gtr:otherNames>Zanelli J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>1E2FD104837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C35127CA-FE9E-4AD9-91D0-C4AED4C3A1C0</gtr:id><gtr:title>Usefulness of interim analyses in portending study results in antipsychotic and antidepressant trials.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17d44ba270474f119b4f3461a9697553"><gtr:id>17d44ba270474f119b4f3461a9697553</gtr:id><gtr:otherNames>Rabinowitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>569d054d713ff6.42273735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DE343F9-1685-42C4-A17E-B5C13DA81B04</gtr:id><gtr:title>Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28542df3bb8c46caa604c1306d4e0c74"><gtr:id>28542df3bb8c46caa604c1306d4e0c74</gtr:id><gtr:otherNames>Agid O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>569d055414fb41.24065352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44EF79DD-B530-4FD5-93E5-9CCD7976B608</gtr:id><gtr:title>Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials.</gtr:title><gtr:parentPublicationTitle>Journal of clinical psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e32dbac114694e2bb6186e6f5488ea5"><gtr:id>9e32dbac114694e2bb6186e6f5488ea5</gtr:id><gtr:otherNames>Kinon BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0271-0749</gtr:issn><gtr:outcomeId>q97znSE95YF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05100341-4C4F-454F-BC70-C2FEA2BD6E5E</gtr:id><gtr:title>The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8eeea5612800493cf459b3a9ae2496a2"><gtr:id>8eeea5612800493cf459b3a9ae2496a2</gtr:id><gtr:otherNames>Graff-Guerrero A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>66A89B93F32</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53E22279-4823-4B86-8525-D5E30C555EC6</gtr:id><gtr:title>Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6abc3cc54b479b42dd76ee30f2312c67"><gtr:id>6abc3cc54b479b42dd76ee30f2312c67</gtr:id><gtr:otherNames>Scarr E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>569d054eeff930.19712749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7578FE7B-CF16-4172-A2C2-A43E023211F5</gtr:id><gtr:title>The nature of dopamine dysfunction in schizophrenia and what this means for treatment.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0691a45ce814dfc6ab4c3e6dd94e781"><gtr:id>a0691a45ce814dfc6ab4c3e6dd94e781</gtr:id><gtr:otherNames>Howes OD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>pm_16114_24_22474070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B952C9C-F620-4AA1-BD9B-6EE85A362DDC</gtr:id><gtr:title>Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b41334629001f83efe0d0b2f5c2da2d"><gtr:id>4b41334629001f83efe0d0b2f5c2da2d</gtr:id><gtr:otherNames>Kambeitz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>569d0550b68dc7.37419583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A1DCB56-98D7-424E-87AC-53ABD0A40008</gtr:id><gtr:title>Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response.</gtr:title><gtr:parentPublicationTitle>Journal of clinical psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf280589e2a9a830f80c4348de090dfa"><gtr:id>bf280589e2a9a830f80c4348de090dfa</gtr:id><gtr:otherNames>Bishara D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0271-0749</gtr:issn><gtr:outcomeId>569d0554eee0b7.28590436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A224A75-8799-463F-A1AB-7552F87CF490</gtr:id><gtr:title>Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5956b5d730eb1a108419277901365e5a"><gtr:id>5956b5d730eb1a108419277901365e5a</gtr:id><gtr:otherNames>Englund A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_16114_24_23042808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86C41382-47CC-4471-8BBF-3AA126CBDCF6</gtr:id><gtr:title>The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8eeea5612800493cf459b3a9ae2496a2"><gtr:id>8eeea5612800493cf459b3a9ae2496a2</gtr:id><gtr:otherNames>Graff-Guerrero A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>2C114E3BBD2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3E748A4-0AAD-408D-89D8-934F92BB87AC</gtr:id><gtr:title>The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a112c692b6911db0d25f1d6fe8687c46"><gtr:id>a112c692b6911db0d25f1d6fe8687c46</gtr:id><gtr:otherNames>Leucht S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>569d054fc51b40.61270313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B500289-656D-4C81-9B16-9CCB0A76B695</gtr:id><gtr:title>Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8351ab06ac06ebf444f6bf4346a232c"><gtr:id>b8351ab06ac06ebf444f6bf4346a232c</gtr:id><gtr:otherNames>Demjaha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>569d05543d45c3.24057958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F36F7E2A-2674-4982-A92C-CAF69E8C4941</gtr:id><gtr:title>Clinical trials for negative symptoms--emerging directions and unresolved issues.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94826691463807f1ed1d1842fd16e639"><gtr:id>94826691463807f1ed1d1842fd16e639</gtr:id><gtr:otherNames>Marder SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>569d0553474141.39963608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C96AD38C-64A2-4018-A524-050F94BE99F5</gtr:id><gtr:title>Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a34bed4dcc674485c8692e22b0bc3da"><gtr:id>2a34bed4dcc674485c8692e22b0bc3da</gtr:id><gtr:otherNames>Mondelli V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>pm_16114_24_23321805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>958362D3-F6C8-4DEA-BF35-DA740722E2B6</gtr:id><gtr:title>Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03619b763704fd6cda232055c285197d"><gtr:id>03619b763704fd6cda232055c285197d</gtr:id><gtr:otherNames>Amato D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>EQVfYXbNXeu</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701748</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>2472941E-25F2-45EC-A735-3C0872CE6B26</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.3  Psychological, social and economic factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>